Search studies
9 studies found
203167 Phase 2a in Psoriasis
ELU-4-EA431B-1
Psoriasis Phase 2a clinical study.
204869 Phase 2a/b in Ulcerative Colitis
ELU-4-907C53-1
204869 Phase 2a/b in Ulcerative Colitis
AIMS LEAP Timepoint 1 (T1) and Timepoint 2 (T2)
ELU-4-4D20BB-1
The Longitudinal European Autism Project (LEAP) is currently the largest study in the world to identify variability in autism in terms of behaviour, cognition, co-occurring conditions, outcomes, brain structure/function and genetics. AIMS-LEAP participants have been followed up longitudinally over time, with the current dataset including Timepoint 1 and Timepoint 2 (approx. 12-24-months apart).
AMCUC study
ELU-4-54A576-1
AMCUC study
LUCENT-1 (NCT 03518086)
ELU-4-58F581-1
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
LuxPark
ELU-4-F67092-1
The cohort includes people with Parkinson’s disease, atypical parkinsonism, and healthy controls, who have their state of health regularly monitored by specialists over many years. The participants donate samples of body fluids such as blood or urine. They also take part in clinical examinations that analyze movement sequences and test their attention, memory, vision, speech, and sense of smell.
MIBIPA
ELU-4-E34987-1
Non-invasive microbiome-derived multi-omic biomarkers for the early-stage detection and stratification of Parkinson's disease
OncoTrack study
ELU-4-24D114-1
OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantl...